Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Lola Luo"'
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy
Rate of CR+CRh by subgroup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be902c39ee395a68d595086357bb634
https://doi.org/10.1158/1078-0432.22469381.v1
https://doi.org/10.1158/1078-0432.22469381.v1
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy
Preferred Terms included in grouped terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477f921b3577155839505aca83b12450
https://doi.org/10.1158/1078-0432.22469378
https://doi.org/10.1158/1078-0432.22469378
Autor:
Richard Pazdur, Ann T. Farrell, Kirsten B. Goldberg, Gene M. Williams, Rosane Charlab, Christopher M. Sheth, Yuan-Li Shen, Albert Deisseroth, Donna Przepiorka, Sarah E. Dorff, Ramadevi Gudi, Vicky Hsu, Lola Luo, Kelly J. Norsworthy
The FDA approved ivosidenib (Tibsovo; Agios), a small-molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73f76bad34dda06affe9b958f7b8772b
https://doi.org/10.1158/1078-0432.c.6527243
https://doi.org/10.1158/1078-0432.c.6527243
Autor:
Rosane Charlab, Vicky Hsu, Kelly J. Norsworthy, Ramadevi Gudi, Ann T. Farrell, Gene M. Williams, Kirsten B. Goldberg, Lola Luo, Albert Deisseroth, Sarah E. Dorff, Donna Przepiorka, Richard Pazdur, Yuan Li Shen, Christopher M. Sheth
Publikováno v:
Clinical Cancer Research. 25:3205-3209
The FDA approved ivosidenib (Tibsovo; Agios), a small-molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detec
Autor:
Lola Luo, Yuan Li Shen, Kirsten B. Goldberg, Sriram Subramaniam, Amy E. McKee, Ann T. Farrell, Virginia E. Kwitkowski, Edvardas Kaminskas, Stacy S. Shord, Patricia A. Oneal, Richard Pazdur
Publikováno v:
The Oncologist
The FDA has granted regular approval to vemurafenib for the treatment of adult patients with Erdheim‐Chester Disease (ECD) with BRAFV600 mutation. This article describes the FDA review of the evidence and the clinical implications for this rare pat
Autor:
Lola Luo, Sriram Subramaniam, Nicole J. Gormley, Guoxiang Shen, Lian Ma, Rajeshwari Sridhara, Yuan Li Shen, Richard Pazdur, Stacy S. Shord, Kirsten B. Goldberg, Ann T. Farrell, Vishal Bhatnagar, Amy E. McKee
Publikováno v:
The Oncologist
Multiple myeloma is mostly an incurable disease. The U.S. Food and Drug Administration (FDA) granted daratumumab accelerated approval in November 2015 as monotherapy for patients with multiple myeloma who have received at least three prior lines of t
Autor:
Lola Luo, Kun He, Ingrid Fran, Gideon M. Blumenthal, Richard Pazdur, Steven Lemery, Dickran Kazandjian
Publikováno v:
The Oncologist
The FDA has expanded the crizotinib metastatic non-small cell lung cancer indication to include treatment of patients whose tumors harbor a ROS1 rearrangement. The approval was based on a clinically meaningful, durable objective response rate (66%) i
Publikováno v:
Journal of Clinical Psychopharmacology. 33:420-424
Objective We examined the effectiveness and mood conversion rate of fluoxetine monotherapy in patients with rapid cycling bipolar II depression versus patients with nonrapid cycling bipolar II depression. We hypothesized that there would be reduced a
Publikováno v:
British Journal of Psychiatry. 202:301-306
BackgroundControversy exists over antidepressant use in rapid-cycling bipolar disorder.AimsExploratory analysis of safety and efficacy of fluoxetine v. lithium monotherapy in individuals with rapid- v. non-rapid-cycling bipolar II disorder.MethodRand
Publikováno v:
eGEMs, Vol 1, Iss 3 (2013)
eGEMs
eGEMs
Chronic diseases are often described by stages of severity. Clinical decisions about what to do are influenced by the stage, whether a patient is progressing, and the rate of progression. For chronic kidney disease (CKD), relatively little is known a